ETF Managers Group’s Oramed Pharmaceuticals ORMP Stock Holding History

ETF Managers Group’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$150K	Buy	+68,940	New	+$219K	﹤0.01%	608
2022 Q4	–	Sell	-94,493	Closed	-$612K	–	647
2022 Q3	$612K	Buy	94,493 +7,128	+8%	+$57.7K	0.02%	325
2022 Q2	$393K	Buy	87,365 +38,076	+77%	+$203K	0.01%	553
2022 Q1	$445K	Sell	49,289 -3,864	-7%	-$39.6K	0.01%	489
2021 Q4	$729K	Buy	53,153 +3,229	+6%	+$67.5K	0.01%	415
2021 Q3	$1.11M	Sell	49,924 -3,440	-6%	-$58.6K	0.02%	258
2021 Q2	$714K	Buy	+53,364	New	+$610K	0.01%	324
2020 Q4	–	Sell	-98,486	Closed	-$255K	–	639
2020 Q3	$255K	Buy	98,486 +7,661	+8%	+$26.7K	0.01%	545
2020 Q2	$317K	Buy	+90,825	New	+$305K	0.01%	387
2018 Q2	–	Sell	-13,478	Closed	-$86K	–	567
2018 Q1	$86K	Buy	13,478 +2,244	+20%	+$17.3K	0.01%	326
2017 Q4	$102K	Buy	11,234 +1,792	+19%	+$17.1K	0.01%	239
2017 Q3	$93K	Buy	9,442 +604	+7%	+$5.21K	0.01%	143
2017 Q2	$69K	Buy	+8,838	New	+$66.6K	0.01%	213

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SIGI

Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ETF Managers Group's ORMP Position: Q1 2023 in Review

ETF Managers Group opened a new position in Oramed Pharmaceuticals (ORMP) in Q1 2023: 68,940 shares worth $150K. The stake represents ﹤0.01% of the portfolio and ranks #608 among its holdings. This is a return to the name: ETF Managers Group previously reported a position in ORMP as recently as Q3 2022.

ETF Managers Group first reported a position in ORMP in Q2 2017 and has held it in 13 quarters since. The position peaked at $1.11M in Q3 2021. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

ETF Managers Group held 68,940 shares of Oramed Pharmaceuticals worth $150K as of Q1 2023.
Oramed Pharmaceuticals was a new ETF Managers Group position in Q1 2023.
Oramed Pharmaceuticals made up ﹤0.01% of ETF Managers Group's portfolio in Q1 2023, its #608 holding.
ETF Managers Group first reported a position in Oramed Pharmaceuticals in Q2 2017 and has held it in 13 quarters since.
ETF Managers Group's Oramed Pharmaceuticals position peaked at $1.11M in Q3 2021.
61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.